We next evaluated the in vivo performance of ET58-DOTA-Gd in orthotopic xenogaft mouse models of GPC3-positive (HepG2) or GPC3-negative (SNU449) HCC cells (Figure 4a). This evidence concerns the gene GPC3 and hepatocellular carcinoma.